Clinical trial · Interventional
Use of 18F-PSMA-11 PET for Detection of Lesions in Iodine Refractory Thyroid Cancers
NCT05175404CI-TRIAL-00086722completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Determine the diagnostic value of 18F-PSMA-11 in patients with iodine refractory thyroid cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET/CT scan F18-PSMA-11 | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Overal Trial
- description
- only one arm in this trial
- interventionNames
- Diagnostic Test: PET/CT scan F18-PSMA-11
Primary outcomes (1)
- measure
- Demonstrate uptake of 18F-PSMA-11 in RAI-RTC
- timeFrame
- 60 minutes +- 5 minutes after injection 18F-PSMA-11
- description
- Confirmation in PET-scan that lesions in RAI-RTC show uptake of 18F-PSMA-11, above background activity in the bloodpool.
Secondary outcomes (7)
- measure
- Perform a semi-quantitative analysis of radiotracer uptake in lesions.
- timeFrame
- 60 minutes +- 5 minutes after injection 18F-PSMA-11
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient is 18 years or older. * Signed Informed Consent. * Subject is diagnosed with a histologically confirmed differentiated thyroid carcinoma, that is considered RAI refractory. There is evidence of persisting or recurrent disease, based on serum thyroglobulin levels and/or medical imaging. * Subject should have a routine clinical 18F-FDG PET/CT performed within two months prior to the study scan. * Female patients should be either post-menopausal, surgically sterile, or using highly effective contraceptives (methods that can achieve a failure rate of less than 1%: combined hormonal contraception, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence). Exclusion Criteria: * Patient has a known other active malignancy. * Subject is potentially pregnant (urinary test can be performed in case of doubt) or breastfeeding. * Patient is mentally or legally incapacitated.
References
Publications (1)
- RESULTVan den Broeck B, Debacker JM, Bauters W, Creytens D, Ferdinande L, Huvenne W, Lapauw B, Schelfhout V, Van Laeken N, Verroken C. Potential application of [18F]AlF-PSMA-11 PET/CT in radioiodine refractory thyroid carcinoma. EJNMMI Res. 2024 Sep 12;14(1):82. doi: 10.1186/s13550-024-01148-9. PMID 39264376